

## CONTENTS

Page No.

DEDICATION	.....	ii
INDEX	.....	iii
LIST OF TABLES	.....	vi
LIST OF FIGURES	.....	vii
ACKNOWLEDGEMENTS	.....	lx
DECLARATION	.....	x
CERTIFICATE	.....	xi
ABSTRACT	.....	xii
ABBREVIATIONS	.....	xv

### CHAPTERS

<b>1.0 INTRODUCTION AND LITERATURE REVIEW</b>		<b>1 – 64</b>
Invasive fungal infections	.....	1
Infection with candida species	.....	2
Infection with Aspergillus species	.....	3
Classification of antifungal drugs	.....	7
Polyene antibiotics	.....	13
Amphotericin B	.....	16
Toxicity associated with Amphotericin B therapy	.....	22
Lipid fomulation of amphotericin B	.....	31
1. Liposomes	.....	31
2. Long circulatory amphotericin B liposomes	.....	41
3. Amphotericin B lipid complex	.....	44
4. Amphotericin B colloidal dispersion	.....	48
5. AmBisome	.....	51
In-Situ preparation of liposomes	.....	54
Incorporation of $\beta$ -Cyclodextrin	.....	55
Formation of inclusion complex	.....	58
Pharmacokinetics of liposome entrapped inclusion complex (Amphotericin/ $\beta$ -CDs) and lipid interactions	.....	62
<b>2.0 SCOPE AND PLAN OF WORK</b>		<b>65 – 70</b>
2.1 Scope of work	.....	65
2.2 Plan of work	.....	68
<b>3. MATERIALS AND METHODS</b>		<b>71 – 86</b>
3.1 Chemicals	.....	71
3.2 Animals	.....	72
3.3 Culture of Aspergillus	.....	72
3.4 Animal model for aspergillosis	.....	72
3.5 Preparation of liposome	.....	72
3.5.1.1 Formation of AmB; $\beta$ -CD inclusion complex	.....	72

3.5.1.2.	Entrapment of inclusion complex into liposome	74
3.5.2.	Optimization of formulation condition	77
3.5.3.	Incorporation of Amphotericin B into liposomes	77
3.6	Evaluation of Proliposome based liposomal vesicles (PBLV)	78
3.6.1.	Intercalation efficiency of drug in PBLV	78
3.6.2.	Entrapment efficiency of inclusion complex in PBLV.	78
3.6.3.	Structural organization of proliposome mixtures	78
3.6.4.	<sup>31</sup> P – NMR Measurements	79
3.6.5.	particle size analysis.	79
3.6.6.	transmission electron microphotography	79
3.6.7.	partition coefficient measurement.	80
3.6.8.	<u>in-vitro</u> drug release profiles.	80
3.6.9.	<u>in-vitro</u> drug leaching studies.	81
3.6.10	Product shelf life determination.	81
3.6.11	Toxicity studies.	81
3.6.11.1	<u>In-vitro</u> toxicity.	81
3.6.11.2	Nephrotoxicity of AmB <sub>DOC</sub>	82
3.6.11.3	Determination of LD <sub>50</sub> .	82
3.6.12	Evaluation of therapeutic efficiency.	83
3.6.13	<u>In-vivo</u> tissue distribution studies.	83
3.6.14	Influence of lipid dose on plasma pharmacokinetics	84
3.6.15	Statistical analysis.	85

#### 4. RESULTS

87- 212

4.1	Preparation and optimization.	87
4.1.1.	Formation of inclusion complex.	87
4.1.2.	Entrapment of inclusion complexes into egg phosphatidylcholine (EPC) Liposome	92
4.1.3.	Entrapment of inclusion complexes into Dioleoyl phosphatidyl choline (DOPC) liposome	108.
4.2	Evaluation of proliposome based liposomal vesicle.	116
4.2.1.	Structural organization of proliposome mixture.	116
4.2.2.	Intercalation of amphotericin B and entrapment efficiency of 6-Carboxyfluorescein in proliposome based liposome (PBLV).	122
4.2.2.	Determination of size of PBLV.	122
4.2.3.	<u>In-Vitro</u> drug release studies.	130
4.2.4.	<u>In-Vitro</u> drug leaching studies.	140
4.2.5.	Product shelf life stability studies.	145
4.2.6.	Toxicity studies.	152
4.2.6.1.	<u>In-Vitro</u> toxicity of AmB <sub>DOC</sub> and PBLV to erythrocytes.	152
4.2.6.2.	<u>In-Vivo</u> toxicity of AmB <sub>DOC</sub> and PBLV.	157
4.2.6.2.a.	Nephrotoxicity of AmB <sub>DOC</sub> and PBLV.	157
4.2.6.2.b	Determination of LD <sub>50</sub> .	157
4.2.7.	Treatment of infected mice and evaluation of therapeutic efficacy.	164
4.2.8.	Pharmacokinetic of amphotericin B when delivered through proliposome based liposomal vesicles in normal and <i>A. fumigatus</i> infected mice.	167
4.2.8.1	Recovery of Amphotericin B in various	

	tissues and plasma.	167
	4.2.8.2. Plasma pharmacokinetic of amphotericin B delivered through deoxycholate suspension and proliposome based liposomal vesicles (in normal mice).	169
	4.2.8.3. Tissue distribution pattern of different liposomal AmB in normal mice.	171
	4.2.8.4. Tissue distribution pattern of different liposomal AmB in infected mice.	178
	4.2.9. Influence of varying lipid dose on plasma pharmacokinetics of PBLV entrapped (AmB- $\beta$ CD) inclusion complexes.	202
<b>5.</b>	<b>DISCUSSION</b>	<b>213– 235</b>
	- Formation of inclusion complexes.	213
	- Liposome entrapped inclusion complexes.	213
	- Stability studies :	
	* <u>In-Vitro</u> drug release studies.	218
	* <u>In-Vitro</u> drug leaching studies.	219
	* Product shelf life stability.	219
	- Toxicity and therapeutic efficacy of amphotericinB delivered through proliposome based liposomal vesicles (PBLV) in the treatment of experimental murine aspergillosis	220
	- Pharmacokinetics of amphotericinB when delivered through proliposome based liposomal vesicles in normal and A fumigatus infected mice	226
	- Influence of lipid dose on plasma pharmacokinetics of PBLV (AmB – HPBCD/SBEBCD) .	231
<b>6.</b>	<b>SUMMARY AND CONCLUSIONS</b>	<b>236 – 245</b>
	- Summary	236
	- Conclusions	244
<b>7.</b>	<b>LIST OF REFERENCES</b>	<b>246 – 266</b>
<b>8.</b>	<b>LIST OF PUBLICATIONS</b>	<b>267</b>